15:54 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS Primate studies suggest combining CD4 mimetics with HIV gp120-based vaccines could help prevent HIV. In macaques challenged with simian human immunodeficiency virus (SHIV) immunized with HIV gp120 variants, a CD4 mimetic prevented infection in...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five disease-associated...
01:01 , Apr 28, 2017 |  BC Innovations  |  Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...
07:00 , Mar 19, 2015 |  BC Innovations  |  Product R&D

AAV for HIV

On top of the problem of creating an HIV vaccine against a rapidly mutating virus, immunologists have been stumped for many years by the fact that preventing access to CD4 - HIV's key entry point...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Clinical News

HVTN 100: Phase I/II started

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN) began the placebo-controlled, South African Phase I/II HVTN 100 trial to evaluate 8 injections of HVTN 100 from...
02:18 , Feb 20, 2015 |  BC Extra  |  Clinical News

NIAID, HVTN launch African trial of HIV vaccine

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN) started the Phase I/II HVTN 100 trial in South Africa to evaluate combination vaccine HVTN 100 to prevent HIV...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Not applicable In vitro studies suggest inducing an IgG3 response against HIV antigens could help...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

ALVAC HIV vaccine: Additional Phase III data

Additional data from the U.S. Army Surgeon General-sponsored, double-blind, Thai Phase III RV144 trial in 16,402 adult volunteers showed that Sanofi Pasteur S.A.'s ALVAC HIV vaccine boosted by the AIDSVAX B/E gp120 vaccine missed...
07:00 , Oct 26, 2009 |  BioCentury  |  Product Development

Correlates and Endpoints

Details matter. While the first reports on a combination HIV vaccine suggested proof that both a T cell and an antibody response are needed to provide protection, the complete data disclosed last week are far...
07:00 , Oct 26, 2009 |  BioCentury  |  Finance

Ebb & Flow

Despite the brutal fundraising environment, New Enterprise Associates is close to wrapping up its 13th fund. According to an SEC filing, the firm has raised $2.46 billion of a planned $2.5 billion, which would put...